Plné znění - 36/2019 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod dopingu pro rok 2018 - Mezinárodní standard)

36/2019 Sb. m. s.

Sdělení

INFORMACE

36

XXXXXXX

Xxxxxxxxxxxx xxxxxxxxxxxx věcí,

kterým xx xxxx x xxxxxxxx sdělení Xxxxxxxxxxxx xxxxxxxxxxxx věcí x. 58/2007 Xx. m. x. x x. 46/2008 Sb. x. x.

Xxxxxxxxxxxx zahraničních věcí xxxxxxx, xx xxx 1. října 2017 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX xxxxxxxx xxxxxxxxx xxxxxx xxxxx Přílohy X - Xxxxxx xxxxxxxxxx látek a xxxxx xxxxxxx xxx xxx 2018 - Xxxxxxxxxxx standard Mezinárodní xxxxxx xxxxx xxxxxxx xx sportu¹⁾.

S xxxxx xxxxxx Xxxxxxx X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx podepsal xxxxxxx o přijetí xxxx Xxxxxxx X Xxxxxx xxxxxxxxxx.

Xxxx xxxxx Xxxxxxx X xxxxxxxxx x xxxxxxxx x xxxxxxx s článkem 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2018. Xxx Xxxxxx xxxxxxxxx xxxxxxxxx nové xxxxx Xxxxxxx I x xxxxxxxx dne 5. xxxxxx 2019.

Xxxx xxxxxx xxxxxx xxxxx Xxxxxxx X x xxxxxxxx xxxxxxxx xxxxxx xxxxx Xxxxxxx X xxxxxx xx 1. xxxxx 2017 x xxxxxxxxx xxx č. 80/2017 Sb. m. s.

Anglické xxxxx xxxxxx znění Xxxxxxx X x xxxx xxxxxxx do xxxxxxx xxxxxx xx xxxxxxxxx xxxxxxxx.

XXXXXXX

XXXXXXXXXXXXX

XXXXXXXX

XXXXXXX XXXXXXXXXXXXX XXXXX

XXXXXX ZAKÁZANÝCH XXXXX X METOD XXXXXXX XXX XXX 2018

MEZINÁRODNÍ XXXXXXXX

Xxxxxxxxx xxxx Xxxxxxx xxxx xxxxxxxxx WADA x xxxx xxxxxxxxxx x xxxxxxxxxx x xxxxxxxxxxxxx.

X xxxxxxx xxxxxxxxxxx xxxxxxxxx mezi xxxxxxxxx x xxxxxxxxxxxx xxxxx xxxx xxxxxxxxxxx xxxxxxxx xxxxx.

Xxxxx Xxxxxx xxxx xxxxxx xx 1. xxxxx 2018 

SEZNAM ZAKÁZANÝCH XXXXX A XXXXX XXXXXXX XXX XXX 2018

XXXXXXX XXXXXXXXXXXXX XXXXX

Xxxxxx xx 1. xxxxx 2018

XXXXX X METODY XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxx xxxxxx 4.2.2 Světového xxxxxxxxxxxxxxx xxxxxx xxxxxxx Xxxxxxxx látky budou xxxxxxxxxx za "Specifické xxxxx" kromě xxxxx xx xxxxxx S1, X2, X4.4, X4.5 x S6(a) x Xxxxxxxxxx metod M1, X2 x X3.

XXXXXXXX XXXXX

X0. NESCHVÁLENÉ LÁTKY

Jakákoliv xxxxxxxxxxxxx xxxxx, xxxxx xxxx xxxxxxxx x xxxxxxxxxxxxx sekcích Xxxxxxx x xxxx xxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx xxxxxxx jakýmkoliv xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. xxxxxx x preklinickém nebo xxxxxxxxx xxxxxx výzkumu xxxx po xxxxxxxx xxxxxxxxxx, xxxxxxxxxx drogy, xxxxx schválené xxxxx xxx xxxxxxxxxxx xxxxxxx), xx zakázána xxxxx.

X1. XXXXXXXXXX XXXXX

Xxxxxxxxxx xxxxx xxxx xxxxxxxx.

1. ANABOLICKÉ XXXXXXXXXX XXXXXXXX (XXX):

(x) Xxxxxxxx* AAS, xxxxxxxxxx:

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3ß,17ß-xxxx);

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx);

1-xxxxxxxxxxx (3α-hydroxy-5α-androst-1-en-17-on);

bolandiol (xxxx-4-xx-3ß, 17ß-xxxx);

xxxxxxxxxx;

xxxxxxx ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol);

dehydrochlormethyltestosteron (4-xxxxxx-17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxxxxxxxxxxxxxxxx (17α-methyl-5α-androst-2-en-17ß-ol);

drostanolon;

ethylestrenol (19-xxxxxxxxx-4-xx-17α-xx);

xxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx (17α-xxxxxx[1,2,5]xxxxxxxxxx[3',4':2,3]-5α-xxxxxxxxx-17ß-xx);

xxxxxxxxx;

4-xxxxxxxxxxxxxxxxxx (4,17ß-dihydroxyandrost-4-en-3-on);

kalusteron;

klostebol;

mestanolon;

mesterolon;

metandienon (17ß-hydroxy-17α-methylandrosta-1,4-dien-3-on);

metenolon;

methandriol;

metasteron (17ß-xxxxxxx-2α,17α-xxxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxxx (17ß-hydroxy-17α-methylestra-4,9-dien-3-on);

methyl-1-testosteron (17ß-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx);

xxxxxXxxxxxxxxxxx;

xxxxxxxxxx (xxxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

1-xxxxxxxxxxx (17ß-hydroxy-5α-androst-1-en-3-on);

tetrahydrogestrinon (17-hydroxy-18α-homo-19-nor-17α-pregna-4,9,11-trien-3-on);

trenbolon (17ß-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

x. Endogenní** XXX, xxxxx jsou xxxxxx exogenně:

Androstanolon (5α-dihydrotestosteron, 17ß-xxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxx (androst-5-en-3ß,17ß-diol);

androstendion (xxxxxxx-4-xx-3,17-xxxx);

xxxxxxxx;

xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx);

xxxxxxxxx;

19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx);

19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx);

xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, DHEA, 3ß-hydroxyandrost-5-en-17-on);

testosteron;

a xxxxxx xxxxxxxxxx x xxxxxxx, xxxxxx, xxx xx x omezením xxxxx xx ně:

5α-androstan-3α,17α-diol;

5α-androstan-3α,17ß-diol;

5α-androstan-3ß,17α-diol;

5α-androstan-3ß,17ß-diol;

5ß-androstan-3α,17ß-diol;

5α-androst-2-en-17-on;

androst-4-en-3α,17α-diol;

androst-4-en-3α,17ß-diol;

androst-4-en-3ß,17α-diol;

androst-5-en-3α,17α-diol;

androst-5-en-3α,17ß-diol;

androst-5-en-3ß,17α-diol;

4-androstendiol (xxxxxxx-4-xx-3ß,17ß-xxxx);

5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx);

xxxxxxxxxxx;

xxx-xxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

3ß-xxxxxxx-5α-xxxxxxxxx-17-xx;

7α-xxxxxxx-XXXX;

7ß-xxxxxxx-XXXX;

7-xxxx-XXXX;

19-xxxxxxxxxxxxxx;

19-xxxxxxxxxxxxxxxxx.

2. Xxxxxxx xxxxxxxxxx látky, xxxxxxxxxx:

Xxxxxxxxxxx; xxxxxxxxxx xxxxxxxxxx androgenových xxxxxxxxx (SARM, xxxx. xxxxxxx, XXX-4033, ostarin x XXX140); xxxxxxx; xxxxxxx x xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.

Xxx účely xxxxxxx xxxx sekce: * "xxxxxxxx" xx xxxxxxxx x xxxxx, kterou xxxx xxxxxxxx xxxxxxxxx xxxxxxxxxxx. ** "xxxxxxxxx " xx xxxxxxxx x xxxxx, xxxxxx tělo normálně xxxxxxxxx produkuje.

S2. PEPTIDOVÉ XXXXXXX, RŮSTOVÉ XXXXXXX, XXXXXXXX XXXXX X XXXXXXXX

Xxxxxxxxxxx xxxxx a xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx jsou zakázány:

1. Xxxxxxxxxxxxx (XXX) x xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx, xxxxxx, xxx xx x xxxxxxxx pouze xx ně:

1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx, xxxx

xxxxxxxxxxxx (xXXX); erytropoetiny (XXX); xxxxxxxxxx založené na XXX (XXX-Xx, xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX)); XXX-xxxxxxxxx xxxxxxxxxx x jejich xxxxxxxxxx (xxxx. XXXX 530 x xxxxxxxxxxx).

1.2 Xxxxxxxxx prostředky xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxx.

xxxxx; xxxxxx; molidustat; xxxxxxxxxx (XX-4592); xenon.

1.3 Xxxxxxxxxx GATA, xxxx.

X-11706.

1.4 Xxxxxxxxxx XXX - xxxx (TGF - β), např.

luspatercept; xxxxxxxxxxx.

1.5 Xxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx. xxxx.

xxxxxx EPO; xxxxxxxxxxxxx EPO.

2. Peptidové xxxxxxx x xxxxxxxxx xxxxxxxxxx

2.1 Xxxxxxxxxxxxxxxxxx (XX) x luteinizační xxxxxx (XX) a jejich xxxxxxxxxx faktory, xxxx. xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, leuprorelin, xxxxxxxxx x xxxxxxxxxxx, u xxxx.

2.2 Kortikotropiny x xxxxxx xxxxxxxxxx xxxxxxx, xxxx. kortikorelin.

2.3 Xxxxxxx xxxxxx (XX), xxxx xxxxxxxxx x xxxxxxxxxx xxxxxxx, včetně, ale xx x xxxxxxxx xxxxx xx xx:

xxxxxxxxx xxxxxxxxx xxxxxxx, xxxx. XXX-9604 a hGH 176-191; hormon xxxxxxxxxx xxxxxxx xxxxxx (GHRH) x xxxx xxxxxxx, xxxx. XXX-1295, xxxxxxxxxx x tesamorelin; sekretagogy xxxxxxxxx hormonu (GHS), xxxx. xxxxxxx x xxxxxxxx ghrelinu, xxxx. xxxxxxxxxx, xxxxxxxxxx a xxxxxxxxxxx; xxxxxxxxxx peptidy xxxxxxxxx xxxxxxx (GHRP), xxxx. xxxxxxxxxxxx, GHRP-1, XXXX-2 (pralmorelin), GHRP-3, XXXX-4, GHRP-5, XXXX-6 x xxxxxxxxx.

3. Xxxxxxx xxxxxxx x xxxxxxxxxx xxxxxxxxx xxxxxxx, xxxxxx, xxx xx x xxxxxxxx pouze xx xx:

xxxxxxxxxxxxx růstové faktory (XXXx);

xxxxxxxxxxxx xxxxxxx xxxxxx (XXX);

xxxxxxxx podobný xxxxxxx xxxxxx-1 (IGF-1) x xxxx xxxxxxx

xxxxxxxxxx xxxxxxx xxxxxxx (MGF);

růstový xxxxxx xxxxxxxx z xxxxxxxx xxxxxxxx (PDGF);

thymosin- β4 x jeho xxxxxxxx, xxxx. XX-500;

xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (VEGF).

Další xxxxxxx xxxxxxx a modulátory xxxxxxxxx xxxxxxx ovlivňující xxxxxxx xxxx degradaci xxxxxxxx xxxxx, xxxxx x xxxxxx, xxxxxx xxxxxxxx, xxxxxxx energie, xxxxxxxxxxxxx xxxxxxxx nebo xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx.

X3. XXXX2- XXXXXXXX

Xxxxxxx xxxxxxxxxx x neselektivní xxxx-2 agonisté, včetně xxxxx optických xxxxxxx, xxxx zakázáni.

Zahrnují (xxx xx x xxxxxxxx xxxxx na xx):

Xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; salmeterol; xxxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx.

Xxxxxxxx xxxx:

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx za 24 xxxxx v oddělených xxxxxxx, xxxxxxxxxxxxxxxx 800 xxxxxxxxxx xxxxx xxxxxxx 12 hodin xx xxxxxxxxx xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx dodaná xxxxx 54 xxxxxxxxxx za 24 xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 200 xxxxxxxxxx xx 24 xxxxx.

Xxxxxxxxxx xxxxxxxxxxx x xxxx x xxxxxxxxxxx xxxxx xxx 1000 xx/xx x xxxxxxxxxx formoterolu x xxxx x xxxxxxxxxxx xxxxx xxx 40 xx/xx xxxxxx xxxxxxxxxx xx zamýšlené xxxxxxxxxxxx xxxxxxx, ale xxxx xxxxxxxxxx za xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx xxxxxxxxx neprokáže xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx studií, xx xxxxxxxxxx xxxxxxxx xxx xxxxxxxx xxxxxxxxxxxxx xxxxxx (x xxxxxxxx) xxxxx, než xxxx xxxxxxx maximální dávka.

S4. XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX

Xxxxxxxx xxxx xxxxxxxxxxx xxxxxxxxx x metabolické xxxxxxxxxx:

1. Inhibitory xxxxxxxx, xxxxxxxxxx:

Xxxxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx);

xxxxxxxx-3,5-xxxx-7-17-xxxx (arimistan);

4-androsten-3,6,17-trion (6-xxx);

xxxxxxxxx;

xxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx, xxx ne x omezením xxxxx xx xx.

2. Selektivní xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), zahrnující:

Raloxifen;

xxxxxxxxx;

xxxxxxxxx, xxx xx x xxxxxxxx pouze xx xx.

3. Xxxxxxx xxxxxxxxxxxxxx xxxxx zahrnující:

Cyklofenil;

fulvestrant;

klomifen, xxx xx x omezením xxxxx na ně.

4. Xxxxx xxxxxxxxxxxx xxxxxx(x) xxxxxxxxxx včetně xxxxxxxxxx xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx ně.

5. Xxxxxxxxxxx xxxxxxxxxx:

5.1 Xxxxxxxxxx XXX-xxxxxxxxxx xxxxxxxxxxxxx (XXXX), xxxx. XXXXX; x Agonisté Xxxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx (XXXXδ), xxxx. 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio)phenoxy) kyselina xxxxxx (XX1516, XX501516);

5.2 xxxxxxxx x mimetika xxxxxxxx;

5.3 xxxxxxxxx;

5.4 xxxxxxxxxxxx.

X5. XXXXXXXXX X XXXXXXXXX XXXXX

Xxxxxxxxxxx xxxxxxxxx a xxxxxxxxx látky xxxx xxxxxxxx, stejně jako xxxxx xxxxx s xxxxxxxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Xxxxxxxx:

• Xxxxxxxxxxxx; plasmaexpandery (xxxx. xxxxxxxxxx xxxxxx xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx x xxxxxxxxx); probenecid, xxx xx x omezením xxxxx na xx.

• Xxxxxxxxxxxx; xxxxxxxx; bumetanid; xxxxxxxxx; xxxxxxxxxxxx; indapamid; kanrenon; xxxxxxxx xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxxxxx; xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx); xxxxxxxxxx x vaptany (xxxx. xxxxxxxxx), ale xx s omezením xxxxx xx xx.

X xxxxxxxx:

• xxxxxxxxxxxx; xxxxxxxxx x xxxxxx podání xxxxxxxxxx xxxxxxxxxxxxxx (xxxx. dorzolamidu x xxxxxxxxxxxx)

• Xxxxxxxxx podání xxxxxxxxxxxx xxx xxxxx xxxxxxxxx

Xxxxx xxxxxxxxxxx xxxxxxxx xxxxx se stanoveným xxxxxxxx xxxxxxx (xx. xxxxxxxxxx, xxxxxxxxxx, xxxxx, xxxxxxx, metylefedrin a xxxxxxxxxxxxx) xx Vzorku Xxxxxxxxx kdykoliv xxxx xxxxxxxx Při Soutěži xx xxxxxxx x xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx, xxxx xxxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx, pokud Xxxxxxxxx xxxx xxxxxxxxxx Xxxxxxxxxxxxx xxxxxxx (TV) xx xxxx xxxxx xxxxx k xx, xxxxx xxx xxxx xxxxxxx na diuretikum xxxx xxxxx xxxxxxxxx xxxxx.

XXXXXXXX XXXXXX

X1. XXXXXXXXXX X KRVÍ X XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxx xxxx xxxxxxxxxxxxx jakéhokoliv množství xxxxxxxxx, alogenní (homologní) xxxx xxxxxxxxxxx krve xxxx xxxxxxxxx xxxxxxx x jim xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx xx oběhového xxxxxxx.

2. Xxxxx zvyšování spotřeby, xxxxxxx nebo xxxxxxx xxxxxxx.

Xxxxxxxxxx:

xxxxxxxxxxxx hemoglobinové xxxxxxxx (xxxx. xxxxxx xxxxxxxx xxxxxxxx xx hemoglobinu x xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x efaproxiral (XXX13), ale xx x xxxxxxxx xxxxx xx xx. Xxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxx xxxx.

3. Jakákoliv xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx xxxx s xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx chemickými způsoby.

M2. XXXXXXXX X FYZIKÁLNÍ XXXXXXXXXX

Xxxxxxxx je následující:

1. Xxxxxxxxx, xxxx Xxxxx x Xxxxxx, xx xxxxxx xxxxxxx integritu x xxxxxxxx Vzorků xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx. Xx xxxxxxxx xxxxxx x/xxxx xxxxxx (xxxx. xxxxxxxxxx) xxxx, xxx ne x xxxxxxxx xxxxx xx xx.

2. Nitrožilní xxxxxx x/xxxx xxxxxxx xxxx xxx celkem 100 xx za 12 xxxxx kromě xxxxxx xxxxxxxxx xxxxxxxxx v xxxxxxx xxxxxxxxxxxx zákroků, xxxxxxxxxxxxx zákroků xxxx xxxxxxxxxx xxxxxxxxxxxxxx metod.

M3. XXXXXX DOPING

Z důvodu xxxxxxxxxx xx xxxxxxx xxxxxxxxxxx výkonu xx xxxxxxxx následující:

1. Xxxxxxx xxxxxxxx nukleových xxxxxxx xxxx jejich xxxxxxx;

2. Xxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx, xxxxxxxxxxx k xxxxxxxxxxx xxxxxxxx genomu x/xxxx k xxxxxxxxxxxx xxxx xxxxxxxxxxxx regulaci xxxxxx exprese.

3. Xxxxxxx xxxxxxxxxx xxxx geneticky xxxxxxxxxxxxxx buněk;

LÁTKY X XXXXXX ZAKÁZANÉ XXX XXXXXXX

Xxxxx xxxxxxxxx X0 xx X5 x X1 až X3 xxxxxxxxx xxxx

xxxx Xxx Xxxxxxx xxxxxxxx x xxxxxxxxxxx skupiny:

ZAKÁZANÉ LÁTKY

S6. XXXXXXXXXXX

Xxxxxxx stimulancia xxxxxx xxxxx xxxxxx případných xxxxxxxxx xxxxxxx, např. x- a X-, xxxx xxxxxxxx.

Xxxxxxxxxxx zahrnují:

(a) Xxxxxxxxxxxx xxxxxxxxxxx:

Xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx /4-xxxxxxxxxxxxxx (xxxxxxxx)/;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx (x-);

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxxxx;

x-xxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx.

Xxxxxxxxxxxx, které xxxx xxxxxxxx uvedeno x tomto xxxxxxxx, xx Xxxxxxxxxxx xxxxxx.

(x) Xxxxxxxxxx stimulancia.

Zahrnují (ale xx x xxxxxxxx xxxxx xx xx):

Xxxxxxxxx (xxxxxxxxx)****;

xxxxxxxxxxx;

xxxxxxxxxxxxxxxxx;

1,3-xxxxxxxxxxxxxxxx;

xxxxxxx***;

xxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx x xxxx xxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxx;

xxxxx**;

xxxxxxx x xxxx analoga (xxxx. xxxxxxxx, xxxxxxxxx x xxxx-xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxxxx***;

xxxxxxxxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

4-xxxxxxxxxx-2-xxxx (xxxxxxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxx (metylsynefrin);

pemolin;

pentetrazol;

propylhexedrin;

pseudoefedrin*****;

selegilin;

sibutramin;

strychnin;

tenamfetamin (xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxx

x další látky x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.

S xxxxxxxx:

• xxxxxxxxx

• xxxxxxxx xxxxxxxxx v případě xxxxxx místního/očního xxxxxxx x stimulancií zahrnutých xx Monitorovacího programu xxx xxx 2018*.

* Xxxxxxxxx, xxxxxxxxxx, fenylpropanolamin, xxxxxx, xxxxxxx, xxxxxxxxx x xxxxxxxx: Xxxx xxxxx jsou xxxxxxxx xx Monitorovacího programu 2018 a nejsou xxxxxxxxxx xx Xxxxxxxx xxxxx.

** Katin: xx xxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxx xxx 5 xxxxxxxxxx v 1 xx moči.

*** Xxxxxxx a xxxxxxxxxxxxx: xxxx xxxxxxxx při xxxxxxxxxxx xxxxx xxx 10 xxxxxxxxxx x 1 xx xxxx.

**** Xxxxxxxxx (epinefrin): xxxx xxxxxxx při xxxxxxxx xxxxxx, xxxx. xxxxx, xxxx aplikace nebo xxxx xxxxxx xxxxxxxx x xxxxxxxxx anestetiky.

***** Xxxxxxxxxxxxx: xx xxxxxxx, xxxxx xxxx koncentrace x moči xx xxxxx xxx 150 xxxxxxxxxx xx xxxxxxxx.

X7. XXXXXXXXX

Xxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxx:

Xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx(xxxxxx);

xxxxxxxx x xxxx xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx.

X8. XXXXXXXXXXX

Xxxxxxxxxxx xxxxxxxxxxx xxxx zakázané:

• Přírodní xxxxxxxxxxx, xxxx. hašiš, xxxxxx x xxxxxxxxx.

• Xxxxxxxxxx kanabinoidy, xxxx. xxxxx9-xxxxxxxxxxxxxxxxxxx (XXX) x xxxxxxx xxxxxxxxxxxxxx.

Xxxxx: xxxxxxxxxxxx

X9. XXXXXXXXXXXXXXX

Xxxxxxx xxxxxxxxxxxxxxx xxxxxxxx xxxxxx, xxxxxxxx, xxxxxxxxxx xxxx xxxxxxxxxxxxx xxxxxxxx xxxx zakázané.

Včetně, xxx xx x xxxxxxxx xxxxx na xx:

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx.

XXXXX XXXXXXXX V URČITÝCH XXXXXXXX

X1. XXXX-XXXXXXXXX

Xxxx-xxxxxxxxx jsou xxxxxxxx xxxxx x xxxxxxxxxxxxx xxxxxxxx Při Xxxxxxx, x xxx xx to xxxxxxxx x Xxxx xxxxxx.

• Xxxxxxxxxxxx xxxxx (FIA)

• Billiard (všechny xxxxxxxxxx) (WCBS)

• Golf (XXX)

• Xxxxxxxxxxx (XX)*

• Xxxxxxxx (FIS) - xxxxx xx xxxxxx x xxxxxxxxxxx xxxxxxxx-xxxxx x U-rampa, x xxxxxxxxx U-rampa a "xxx xxx"

• Xxxxxxxx xxxxxx (xxxxxxxxx potápění) (CMAS) x xxxxxxxxxxxx xxxxxxxxxx xxxx s ploutvemi xxxx bez ploutví, xxxxxxxxx xxxxx s xxxxxxxxx xxxx xxx xxxxxxx, xxxx xxxxxxxxx, xxxx xxxx, xxxxxxxxxxxx, xxxxxxxx xxxxx, xxxxxxx xxxxxxxx na xxxx x variabilní xxxx.

• Xxxxxxx (XXXX, XXX)*

• Xxxxx (XXX)

* Xxxxxxxx také Xxxx xxxxxx

Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:

Xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxxx;

xxx xx x xxxxxxxx xxxxx na xx.

Informace

Právní xxxxxxx x. 36/2019 Xx. x. x. xxxxx xxxxxxxxx xxxx 26.7.2019.

Xxxxxx předpis x. 36/2019 Sb. x. x. xxx xxxxxx xxxxxxx předpisem č. 32/2023 Sb. m. s. x xxxxxxxxx xx 22.8.2023.

Xxxxx jednotlivých xxxxxxxx xxxxx jiných xxxxxxxx xxxxxxxx v xxxxxxxx není xxxxxxxxxxxxx, xxxxx xx jich xxxxxx xxxxxxxxx xxxxx xxxxx uvedeného xxxxxxxx xxxxxxxx.

1) Xxxxxxxxxxx xxxxxx xxxxx dopingu xx xxxxxx, xxxxxxx dne 19. xxxxx 2005 x Xxxxxx, xxxx xxxxxxxxx x xxxxxxxxx xxxxx x s xxxxxxxxx do xxxxxxx xxxxxx xxx č. 58/2007 Sb. m. s.

Xxxx xxxxx xxxxxxxx Úmluvy xx xxxxxxx xxxxxx xxxx xxxxxxxxx xxx č. 46/2008 Sb. m. s.